Utah Medical Products, Inc.
NASDAQ:UTMDMedical - Instruments & Supplies
+$1.10 today
- Market cap
- $205.81M
- Beta
- 0.37
- P/E (TTM)
- 19.6
- EPS (TTM)
- $3.41
- Dividend yield
- 1.85%
Volume 0.02M
Average 0.01M
UTMD Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Utah Medical Products, Inc.NASDAQ: UTMD
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings broadly unchanged from a year ago
Retained earnings stood at $130.26M at the end of Q1 FY2026, up 1.6% from a year earlier and up 1.2% from the prior quarter. Over 3 fiscal years it compounded at +0.7% a year.
Context
- Retained earnings amounted to 104.7% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Retained earnings increased in 1 of the last 3 fiscal years.
What to watch
Whether retained earnings keeps rising in the next quarterly balance sheet after a +1.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- 128.65M USD
- Year-over-year change
- -0.5%
- 4-year CAGR
- +2.8%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 128.65M | -0.5% |
| FY2024 | 2024-12-31 | 129.3M | -6.5% |
| FY2023 | 2023-12-31 | 138.34M | +9.8% |
| FY2022 | 2022-12-31 | 126.01M | +9.3% |
| FY2021 | 2021-12-31 | 115.31M | — |
Retained Earnings vs competitors
How UTMD compares with its peers on the latest reported figures
- Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +1.6% is the 3rd highest of 10, against a peer median of -8.6%.
- Retained earnings amounts to 104.7% of total assets for UTMD, versus a peer median of 222.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $130.26M USD | +1.6% | +0.7% | 104.7% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | -$32.82M USD | -7.5% | — | 114.8% | |
| Mar 2026 | -$60.54M USD | +0.1% | — | 61.4% | |
| Mar 2026 | -$194.54M USD | -62.8% | — | 51.3% | |
| Mar 2026 | -$295.76M USD | -15.6% | — | 401.3% | |
| Mar 2026 | -€322.95M EUR | -34.5% | — | 329.6% | |
| Mar 2026 | -$361.03M USD | -44.5% | — | 87.9% | |
| Mar 2026 | -$366.68M USD | +4.0% | — | 358.3% | |
| Mar 2026 | -$469.58M USD | -8.6% | — | 374.3% | |
| Mar 2026 | -$1.42B USD | +11.6% | — | 534.3% | |
| Peer median (excluding UTMD) | — | -8.6% | — | 222.2% | |
Competitors are the stored peer set for UTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 60.97M | 75.05M | 92.87M | 82.98M | 85.76M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 5.13M | 5.54M | 3.39M | 4.09M | 3.52M |
| Inventory | 6.6M | 8.81M | 9.58M | 8.81M | 7.94M |
| Other Current Assets | 1K | 0 | 429K | 448K | 529K |
| Total Current Assets | 73.16M | 89.92M | 106.27M | 96.33M | 97.74M |
| Property, Plant & Equipment (Net) | 10.62M | 10.22M | 10.55M | 9.76M | 9.91M |
| Goodwill | 14.1M | 13.35M | 13.69M | 13.58M | 14.05M |
| Intangible Assets | 17.76M | 10.38M | 4.95M | 2.87M | 840K |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 42.48M | 33.96M | 29.19M | 26.21M | 24.8M |
| Total Assets | 115.64M | 123.87M | 135.46M | 122.54M | 122.54M |
| Account Payables | 761K | 1.22M | 769K | 543K | 911K |
| Short-term Debt | 0 | 0 | 0 | 56K | 0 |
| Tax Payables | 36K | 337K | 327K | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 96K | 204K | 257K | 55K | 68K |
| Total Current Liabilities | 3.75M | 5.96M | 4.71M | 3.76M | 2.6M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 2.68M | 2.06M | 1.44M | 1.07M | 451K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 1.68M | 1.26M | 698K | 0 | 0 |
| Total Non-current Liabilities | 4.75M | 3.66M | 2.44M | 1.35M | 676K |
| Total Liabilities | 8.5M | 9.62M | 7.15M | 5.11M | 3.27M |
| Common Stock | 37K | 36K | 36K | 33K | 32K |
| Retained Earnings | 115.31M | 126.01M | 138.34M | 129.3M | 128.65M |
| Accumulated OCI | (9.05M) | (12.04M) | (10.66M) | (11.91M) | (9.42M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 107.14M | 114.25M | 128.31M | 117.43M | 119.27M |
| Total Debt | 396K | 341K | 295K | 338K | 225K |
| Net Debt | (60.58M) | (74.71M) | (92.57M) | (82.69M) | (85.53M) |
Utah Medical Products, Inc.
NASDAQ:UTMD
Intrinsic Alpha fair value
Locked
Current Price
$72.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.